

# Garnet L Anderson

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/42020/garnet-l-anderson-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

151  
papers

32,244  
citations

58  
h-index

174  
g-index

174  
ext. papers

36,371  
ext. citations

10  
avg, IF

6.17  
L-index

#	Paper	IF	Citations
151	Design and baseline characteristics of participants in the COcoa Supplement and Multivitamin Outcomes Study (COSMOS).. <i>Contemporary Clinical Trials</i> , <b>2022</b> , 106728	2.3	0
150	Nutritional epidemiology and the Women's Health Initiative: a review. <i>American Journal of Clinical Nutrition</i> , <b>2021</b> , 113, 1083-1092	7	1
149	The association between heart failure and incident cancer in women: an analysis of the Women's Health Initiative. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1712-1721	12.3	4
148	Determinants, circumstances and consequences of injurious falls among older women living in the community. <i>Injury Prevention</i> , <b>2021</b> , 27, 34-41	3.2	3
147	Reply to The Women's Health Initiative; hormone replacement therapy; and Surveillance, Epidemiology, and End Results data. <i>Cancer</i> , <b>2021</b> , 127, 813-814	6.4	
146	Randomized Trial Evaluation of the Benefits and Risks of Menopausal Hormone Therapy Among Women 50-59 Years of Age. <i>American Journal of Epidemiology</i> , <b>2021</b> , 190, 365-375	3.8	10
145	Obesity, Height, and Serum Androgen Metabolism among Postmenopausal Women in the Women's Health Initiative Observational Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2021</b> , 30, 2018-2029	4	0
144	Association of Prediagnostic Frailty, Change in Frailty Status, and Mortality After Cancer Diagnosis in the Women's Health Initiative. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2016747	10.4	6
143	Lights on MsFLASH: a review of contributions. <i>Menopause</i> , <b>2020</b> , 27, 473-484	2.5	7
142	Can dietary self-reports usefully complement blood concentrations for estimation of micronutrient intake and chronic disease associations?. <i>American Journal of Clinical Nutrition</i> , <b>2020</b> , 112, 168-179	7	4
141	Forty-year trends in menopausal hormone therapy use and breast cancer incidence among postmenopausal black and white women. <i>Cancer</i> , <b>2020</b> , 126, 2956-2964	6.4	7
140	Dietary Modification and Breast Cancer Mortality: Long-Term Follow-Up of the Women's Health Initiative Randomized Trial. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1419-1428	2.2	37
139	Prediagnosis social support, social integration, living status, and colorectal cancer mortality in postmenopausal women from the women's health initiative. <i>Cancer</i> , <b>2020</b> , 126, 1766-1775	6.4	6
138	The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women's Health Initiative. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 180, 747-757	4.4	6
137	Dual-Outcome Intention-to-Treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy Trials. <i>American Journal of Epidemiology</i> , <b>2020</b> , 189, 972-981	3.8	4
136	Association of Powder Use in the Genital Area With Risk of Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 49-59	27.4	24
135	Mediation by differential DNA methylation of known associations between single nucleotide polymorphisms and bladder cancer risk. <i>BMC Medical Genetics</i> , <b>2020</b> , 21, 228	2.1	2

134	Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 324, 369-380	27.4	85
133	Guideline-concordant endometrial cancer treatment and survival in the Women's Health Initiative Life and Longevity After Cancer study. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 404-412	7.5	4
132	Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women's Health Initiative Observational Study. <i>Cancer Causes and Control</i> , <b>2019</b> , 30, 1201-1211	2.8	9
131	Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 2051-2060	7.5	11
130	Low-Fat Dietary Pattern among Postmenopausal Women Influences Long-Term Cancer, Cardiovascular Disease, and Diabetes Outcomes. <i>Journal of Nutrition</i> , <b>2019</b> , 149, 1565-1574	4.1	17
129	Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812). <i>Cancer Prevention Research</i> , <b>2019</b> , 12, 481-490	3.2	8
128	Application of blood concentration biomarkers in nutritional epidemiology: example of carotenoid and tocopherol intake in relation to chronic disease risk. <i>American Journal of Clinical Nutrition</i> , <b>2019</b> , 109, 1189-1196	7	17
127	Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 137-145	9.7	28
126	Postmenopausal Androgen Metabolism and Endometrial Cancer Risk in the Women's Health Initiative Observational Study. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz029	4.6	16
125	An Environmental Scan of Biopsychosocial and Clinical Variables in Cohort Studies of Cancer Survivors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2019</b> , 28, 1621-1641	4	2
124	Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone?. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 730-740	7.5	3
123	The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study. <i>PLoS Medicine</i> , <b>2019</b> , 16, e1002724	11.6	38
122	Weight loss and breast cancer incidence in postmenopausal women. <i>Cancer</i> , <b>2019</b> , 125, 205-212	6.4	37
121	The Women's Health Initiative (WHI) Life and Longevity After Cancer (LILAC) Study: Description and Baseline Characteristics of Participants. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2018</b> , 27, 125-137	4.7	23
120	Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials. <i>Sleep</i> , <b>2018</b> , 41,	1.1	45
119	Recommendation to use exact P-values in biomarker discovery research in place of approximate P-values. <i>Cancer Epidemiology</i> , <b>2018</b> , 56, 83-89	2.8	3
118	Low-Fat Dietary Pattern and Cancer Mortality in the Women's Health Initiative (WHI) Randomized Controlled Trial. <i>JNCI Cancer Spectrum</i> , <b>2018</b> , 2, pky065	4.6	9
117	Association of Low-Fat Dietary Pattern With Breast Cancer Overall Survival: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, e181212	13.4	40

116	Low-fat dietary pattern and cardiovascular disease: results from the Women's Health Initiative randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , <b>2017</b> , 106, 35-43	7	47
115	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. <i>Nature Communications</i> , <b>2017</b> , 8, 15724	17.4	50
114	Effects of Yoga and Aerobic Exercise on Actigraphic Sleep Parameters in Menopausal Women with Hot Flashes. <i>Journal of Clinical Sleep Medicine</i> , <b>2017</b> , 13, 11-18	3.1	21
113	Low-Fat Dietary Pattern and Breast Cancer Mortality in the Women's Health Initiative Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2919-2926	2.2	66
112	Sitting, physical activity, and serum oestrogen metabolism in postmenopausal women: the Women's Health Initiative Observational Study. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 1070-1078	8.7	9
111	Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 927-938	27.4	268
110	Anthropometric measures and serum estrogen metabolism in postmenopausal women: the Women's Health Initiative Observational Study. <i>Breast Cancer Research</i> , <b>2017</b> , 19, 28	8.3	15
109	Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	22
108	Use of administrative data to increase the practicality of clinical trials: Insights from the Women's Health Initiative. <i>Clinical Trials</i> , <b>2016</b> , 13, 519-26	2.2	16
107	Circulating Estrogens and Postmenopausal Ovarian Cancer Risk in the Women's Health Initiative Observational Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2016</b> , 25, 648-56	4	33
106	Parity and Oral Contraceptive Use in Relation to Ovarian Cancer Risk in Older Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2016</b> , 25, 1059-63	4	18
105	Serum Estrogens and Estrogen Metabolites and Endometrial Cancer Risk among Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2016</b> , 25, 1081-9	4	59
104	Oral bisphosphonate use and risk of postmenopausal endometrial cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1186-90	2.2	14
103	Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	19
102	Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials. <i>JAMA Oncology</i> , <b>2015</b> , 1, 611-21	13.4	294
101	A Prospective Evaluation of Endogenous Sex Hormone Levels and Colorectal Cancer Risk in Postmenopausal Women. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	74
100	Menopausal hormone therapy and breast cancer mortality: clinical implications. <i>Therapeutic Advances in Drug Safety</i> , <b>2015</b> , 6, 45-56	3.5	24
99	Identifying post-menopausal women at elevated risk for epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2015</b> , 139, 253-60	4.9	10

98	Menopausal Hormone Therapy Influence on Breast Cancer Outcomes in the Women's Health Initiative. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2015</b> , 13, 917-24	7.3	15
97	Obesity and inflammation markers in relation to leukocyte telomere length in a cross-sectional study of persons with Barrett's esophagus. <i>BMC Obesity</i> , <b>2015</b> , 2, 32	3.6	15
96	Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms. <i>Obstetrics and Gynecology</i> , <b>2015</b> , 126, 413-422	4.9	32
95	Optimal cutoffs of obesity measures in relation to cancer risk in postmenopausal women in the Women's Health Initiative Study. <i>Journal of Women's Health</i> , <b>2015</b> , 24, 218-27	3	13
94	Association Between Obesity and Postmenopausal Breast Cancer Risk-Reply. <i>JAMA Oncology</i> , <b>2015</b> , 1, 1171	13.4	
93	Menopausal quality of life: RCT of yoga, exercise, and omega-3 supplements. <i>American Journal of Obstetrics and Gynecology</i> , <b>2014</b> , 210, 244.e1-11	6.4	49
92	Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage. <i>Cancer Causes and Control</i> , <b>2014</b> , 25, 969-76	2.8	23
91	Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. <i>Breast Cancer Research</i> , <b>2014</b> , 16, R30	8.3	19
90	Menopausal hormone therapy and cancer: changing clinical observations of target site specificity. <i>Steroids</i> , <b>2014</b> , 90, 53-9	2.8	27
89	Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study. <i>Annals of Internal Medicine</i> , <b>2014</b> , 160, 594-602	8	36
88	Women's Health Initiative: Statistical Aspects and Selected Early Results <b>2014</b> , 901-913		
87	Efficacy of exercise for menopausal symptoms: a randomized controlled trial. <i>Menopause</i> , <b>2014</b> , 21, 330-8.5	8.5	102
86	Methods for the design of vasomotor symptom trials: the menopausal strategies: finding lasting answers to symptoms and health network. <i>Menopause</i> , <b>2014</b> , 21, 45-58	2.5	47
85	Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett's esophagus cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2014</b> , 23, 2393-403	4	31
84	Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 1058-66	11.5	116
83	Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial. <i>Menopause</i> , <b>2014</b> , 21, 347-54	2.5	47
82	Efficacy of yoga for vasomotor symptoms: a randomized controlled trial. <i>Menopause</i> , <b>2014</b> , 21, 339-46	2.5	70
81	Incidental genetic findings in randomized clinical trials: recommendations from the Genomics and Randomized Trials Network (GARNET). <i>Genome Medicine</i> , <b>2013</b> , 5, 7	14.4	11

80	A Statistical Perspective on Prevention Trials: A View from the Women's Health Initiative. <i>Statistics in Biosciences</i> , <b>2013</b> , 5, 330-343	1.5	1
79	Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). <i>Cancer Causes and Control</i> , <b>2013</b> , 24, 209-15	2.8	83
78	Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 309, 578-86	27.4	62
77	Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 526-35	9.7	143
76	Women's health initiative view of estrogen avoidance and all-cause mortality. <i>American Journal of Public Health</i> , <b>2013</b> , 103, e2	5.1	0
75	Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy. <i>Obstetrics and Gynecology</i> , <b>2013</b> , 121, 172-6	4.9	66
74	Breast tenderness after initiation of conjugated equine estrogens and mammographic density change. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 131, 969-79	4.4	21
73	Treatment of Helicobacter pylori in Latin America [Authors' reply]. <i>Lancet, The</i> , <b>2012</b> , 379, 408-409	4.0	3
72	Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 476-86	21.7	262
71	Obesity and the risk for premenopausal and postmenopausal breast cancer. <i>Cancer Prevention Research</i> , <b>2012</b> , 5, 515-21	3.2	65
70	Migraine history, nonsteroidal anti-inflammatory drug use, and risk of postmenopausal endometrial cancer. <i>Hormones and Cancer</i> , <b>2012</b> , 3, 240-8	5	6
69	Use of alternative time scales in Cox proportional hazard models: implications for time-varying environmental exposures. <i>Statistics in Medicine</i> , <b>2012</b> , 31, 3320-7	2.3	37
68	Changing concepts: Menopausal hormone therapy and breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2012</b> , 104, 517-27	9.7	105
67	14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. <i>Lancet, The</i> , <b>2011</b> , 378, 507-14	4.0	200
66	Hormonal factors and risks of esophageal squamous cell carcinoma and adenocarcinoma in postmenopausal women. <i>Cancer Prevention Research</i> , <b>2011</b> , 4, 840-50	3.2	43
65	Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. <i>Journal of the National Cancer Institute</i> , <b>2011</b> , 103, 951-61	9.7	110
64	Potential role of HE4 in multimodal screening for epithelial ovarian cancer. <i>Journal of the National Cancer Institute</i> , <b>2011</b> , 103, 1630-4	9.7	38
63	Breast Cancer in Postmenopausal Women After Hormone Therapy Reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 305, 466	27.4	

62	Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2327-33	2.2	154
61	Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 305, 267-74	27.4	152
60	Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 1413-21	9.7	84
59	Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 304, 1684-92	27.4	391
58	Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 26-38	9.7	156
57	Lung cancer and hormone replacement therapy [Authors' reply]. <i>Lancet, The</i> , <b>2010</b> , 375, 118-119	4.0	1
56	Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. <i>Gynecologic Oncology</i> , <b>2010</b> , 116, 323-5	4.9	49
55	Lifestyle Factors and Risk of Breast Cancer: A Review of Randomized Trial Findings <b>2010</b> , 23-41		
54	Ambient fine particulate matter exposure and myocardial ischemia in the Environmental Epidemiology of Arrhythmogenesis in the Women's Health Initiative (EEAWHI) study. <i>Environmental Health Perspectives</i> , <b>2009</b> , 117, 751-6	8.4	32
53	Breast cancer after use of estrogen plus progestin in postmenopausal women. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 573-87	59.2	345
52	Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 48-60	9.7	392
51	Multivitamin use and risk of cancer and cardiovascular disease in the Women's Health Initiative cohorts. <i>Archives of Internal Medicine</i> , <b>2009</b> , 169, 294-304		142
50	Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. <i>American Journal of Epidemiology</i> , <b>2009</b> , 170, 12-23	3.8	165
49	Heart rate variability, ambient particulate matter air pollution, and glucose homeostasis: the environmental epidemiology of arrhythmogenesis in the women's health initiative. <i>American Journal of Epidemiology</i> , <b>2009</b> , 169, 693-703	3.8	60
48	Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer. <i>Gynecologic Oncology</i> , <b>2009</b> , 114, 206-9	4.9	10
47	Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. <i>Nature Genetics</i> , <b>2009</b> , 41, 585-96	36.3	393
46	Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. <i>Lancet, The</i> , <b>2009</b> , 374, 1243-51	4.0	219
45	Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. <i>JAMA - Journal of the American Medical Association</i> , <b>2008</b> , 299, 1036-45	27.4	279

44	Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. <i>Cancer Research</i> , <b>2008</b> , 68, 329-37	10.1	171
43	The women's health initiative: lessons learned. <i>Annual Review of Public Health</i> , <b>2008</b> , 29, 131-50	20.6	57
42	The role of antioxidants and vitamin A in ovarian cancer: results from the Women's Health Initiative. <i>Nutrition and Cancer</i> , <b>2008</b> , 60, 710-9	2.8	32
41	Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. <i>American Journal of Epidemiology</i> , <b>2008</b> , 167, 1207-16	3.8	111
40	Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. <i>American Journal of Epidemiology</i> , <b>2008</b> , 167, 1407-15	3.8	111
39	Women's Health Initiative: Statistical Aspects and Selected Early Results <b>2008</b> , 1		
38	Effects of blood collection conditions on ovarian cancer serum markers. <i>PLoS ONE</i> , <b>2007</b> , 2, e1281	3.7	39
37	Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , <b>2007</b> , 99, 1534-43	9.7	160
36	Predicting risk of breast cancer in postmenopausal women by hormone receptor status. <i>Journal of the National Cancer Institute</i> , <b>2007</b> , 99, 1695-705	9.7	103
35	Projecting individualized absolute invasive breast cancer risk in African American women. <i>Journal of the National Cancer Institute</i> , <b>2007</b> , 99, 1782-92	9.7	226
34	Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials. <i>Clinical Trials</i> , <b>2007</b> , 4, 207-17	2.2	19
33	Long-term exposure to air pollution and incidence of cardiovascular events in women. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 447-58	59.2	1319
32	Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. <i>American Journal of Epidemiology</i> , <b>2006</b> , 163, 589-99	3.8	135
31	Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 295, 655-66	27.4	738
30	Low-Fat Diet and Cardiovascular Disease Reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 296, 279	27.4	
29	Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 295, 1647-57	27.4	410
28	Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 295, 643-54	27.4	283
27	Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 295, 629-42	27.4	553



26	Calcium plus vitamin D supplementation and the risk of colorectal cancer. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 684-96	59.2	772
25	Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use. <i>Clinical Breast Cancer</i> , <b>2006</b> , 6 Suppl 2, S58-64	3	23
24	Calcium plus vitamin D supplementation and the risk of fractures. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 669-83	59.2	1366
23	Bead-based ELISA for validation of ovarian cancer early detection markers. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 2117-24	12.9	119
22	Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. <i>Maturitas</i> , <b>2006</b> , 55, 103-15	5	177
21	Concerns about published data from the estrogen-progestin (HT) arm of the WHI. <i>American Journal of Obstetrics and Gynecology</i> , <b>2005</b> , 192, 333; author reply 334	6.4	
20	Statistical issues arising in the Women's Health Initiative. <i>Biometrics</i> , <b>2005</b> , 61, 899-911; discussion 911-41.8	41.8	49
19	Women's Health Initiative: Statistical Aspects and Selected Early Results <b>2005</b> , 1-11		
18	Ethnicity and breast cancer: factors influencing differences in incidence and outcome. <i>Journal of the National Cancer Institute</i> , <b>2005</b> , 97, 439-48	9.7	471
17	Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2004</b> , 291, 1701-12	27.4	3160
16	AIR POLLUTION AND CARDIOVASCULAR DISEASE EVENTS IN THE WOMEN'S HEALTH INITIATIVE OBSERVATIONAL (WHI-OS) STUDY. <i>Epidemiology</i> , <b>2004</b> , 15, S28-S29	3.1	3
15	The case for early detection. <i>Nature Reviews Cancer</i> , <b>2003</b> , 3, 243-52	31.3	860
14	Selecting differentially expressed genes from microarray experiments. <i>Biometrics</i> , <b>2003</b> , 59, 133-42	1.8	145
13	The Women's Health Initiative recruitment methods and results. <i>Annals of Epidemiology</i> , <b>2003</b> , 13, S18-76.4	76.4	556
12	Implementation of the Women's Health Initiative study design. <i>Annals of Epidemiology</i> , <b>2003</b> , 13, S5-17	6.4	538
11	Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2003</b> , 290, 1739-48	27.4	374
10	Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2002</b> , 288, 321-33	27.4	12115
9	Estimation of the correlation between nutrient intake measures under restricted sampling. <i>Biometrics</i> , <b>1999</b> , 55, 711-7	1.8	5

8	Individually randomized intervention trials for disease prevention and control. <i>Statistical Methods in Medical Research</i> , <b>1999</b> , 8, 287-309	2.3	12
7	Approached to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative. <i>Contemporary Clinical Trials</i> , <b>1996</b> , 17, 509-25		74
6	Model Misspecification in Proportional Hazards Regression. <i>Biometrika</i> , <b>1995</b> , 82, 527	2	1
5	A cautionary note on inference for marginal regression models with longitudinal data and general correlated response data. <i>Communications in Statistics Part B: Simulation and Computation</i> , <b>1994</b> , 23, 939-951	0.6	229
4	Effects on response rates and costs of stamps vs business reply in a mail survey of physicians. <i>Journal of Clinical Epidemiology</i> , <b>1993</b> , 46, 455-9	5.7	33
3	Statistical design and monitoring of the Carotene and Retinol Efficacy Trial (CARET). <i>Contemporary Clinical Trials</i> , <b>1993</b> , 14, 308-24		53
2	Two-Stage Experimental Designs: Early Stopping with a Negative Result. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , <b>1992</b> , 41, 181	1.5	37
1	Correlates of maintenance of a low-fat diet among women in the Women's Health Trial. <i>Preventive Medicine</i> , <b>1992</b> , 21, 279-91	4.3	59